Alector Inc
NASDAQ:ALEC

Watchlist Manager
Alector Inc Logo
Alector Inc
NASDAQ:ALEC
Watchlist
Price: 3.94 USD 4.79% Market Closed
Market Cap: 385.8m USD
Have any thoughts about
Alector Inc?
Write Note

Alector Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alector Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Alector Inc
NASDAQ:ALEC
Pre-Tax Income
-$156.7m
CAGR 3-Years
-68%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Alector Inc
Glance View

Market Cap
385.8m USD
Industry
Biotechnology

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

ALEC Intrinsic Value
5.98 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Alector Inc's Pre-Tax Income?
Pre-Tax Income
-156.7m USD

Based on the financial report for Sep 30, 2024, Alector Inc's Pre-Tax Income amounts to -156.7m USD.

What is Alector Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-11%

Over the last year, the Pre-Tax Income growth was -14%. The average annual Pre-Tax Income growth rates for Alector Inc have been -68% over the past three years , -11% over the past five years .

Back to Top